400-888-7502 登錄/注冊購物車(0)

期刊導(dǎo)航

首頁 > SCI期刊 > 醫(yī)學(xué)期刊 > Drug Design Development And Therapy(非官網(wǎng))

收藏該雜志

同大類學(xué)科其它級別期刊：

中科院 1區(qū) 期刊 JCR Q1 期刊中科院 2區(qū) 期刊 JCR Q2 期刊中科院 3區(qū) 期刊 JCR Q3 期刊中科院 4區(qū) 期刊 JCR Q4 期刊

Drug Design Development And Therapy SCIE

國際簡稱：DRUG DES DEV THER 參考譯名：藥物設(shè)計(jì)開發(fā)和治療

主要研究方向：CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY 非預(yù)警期刊審稿周期： 12周，或約稿

《藥物設(shè)計(jì)開發(fā)和治療》(Drug Design Development And Therapy)是一本由Dove Medical Press Ltd.出版的以CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

2區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
256 年發(fā)文量
4.7 IF影響因子
開放是否OA
48 H-index
2007 創(chuàng)刊年份
1 issue/year 出版周期
English 出版語言

Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.

The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.

Specific topics covered by the journal include:

Drug target identification and validation

Phenotypic screening and target deconvolution

Biochemical analyses of drug targets and their pathways

New methods or relevant applications in molecular/drug design and computer-aided drug discovery*

Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)

Structural or molecular biological studies elucidating molecular recognition processes

Fragment-based drug discovery

Pharmaceutical/red biotechnology

Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**

Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development

Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)

Preclinical development studies

Translational animal models

Mechanisms of action and signalling pathways

Toxicology

Gene therapy, cell therapy and immunotherapy

Personalized medicine and pharmacogenomics

Clinical drug evaluation

Patient safety and sustained use of medicines.

[ 查看全部 ]

投稿咨詢加急咨詢

Drug Design Development And Therapy期刊信息

ISSN：1177-8881
出版語言：English
是否OA：開放
出版地區(qū)：ENGLAND
是否預(yù)警：否
出版商：Dove Medical Press Ltd.
出版周期：1 issue/year
創(chuàng)刊時(shí)間：2007
開源占比：0.9689
Gold OA文章占比：97.50%
OA被引用占比：1
出版國人文章占比：0.52
出版撤稿占比：0.0043...
研究類文章占比：80.08%

Drug Design Development And Therapy CiteScore評價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

0.999

1.124

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	24 / 183	87%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	48 / 313	84%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	27 / 157	83%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Drug Design Development And Therapy中科院評價(jià)數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 2區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 3區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 3區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 3區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 3區(qū)

Drug Design Development And Therapy JCR評價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.1%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	55 / 354	84.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.08%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	68 / 354	80.93%

Drug Design Development And Therapy歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Drug Design Development And Therapy中國學(xué)者發(fā)文選摘

1、Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
Author: Zhu, Yuanyuan; Zhang, Wei; Chen, Jing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 1-13. DOI: 10.2147/DDDT.S387246
2、Menthone Exerts its Antimicrobial Activity Against Methicillin Resistant Staphylococcus aureus by Affecting Cell Membrane Properties and Lipid Profile
Author: Zhao, Wenming; Yang, Chengwei; Zhang, Ning; Peng, Yuanyuan; Ma, Ying; Gu, Keru; Liu, Xia; Liu, Xiaohui; Liu, Xijian; Liu, Yumin; Li, Songkai; Zhao, Linjing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 219-236. DOI: 10.2147/DDDT.S384716
3、Evaluation of Chitosan-Oleuropein Nanoparticles on the Durability of Dentin Bonding
Author: Zhao, Shuya; Zhang, Yunyang; Chen, Yun; Xing, Xianghui; Wang, Yu; Wu, Guofeng

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 167-180. DOI: 10.2147/DDDT.S390039
4、Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites
Author: Zhao, Ning; Ma, Yan; Liang, Xiaoxue; Zhang, Yu; Hong, Dacheng; Wang, Ying; Bai, Dong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 579-595. DOI: 10.2147/DDDT.S396649
5、Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer
Author: Zhao, Mei; Fu, Lijuan; Xu, Panling; Wang, Ting; Li, Ping

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 901-917. DOI: 10.2147/DDDT.S397969
6、Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (L?v.) Hutch Against IgA Nephropathy
Author: Zhao, Juanyong; Liu, Haiyang; Xia, Ming; Chen, Qian; Wan, Lili; Leng, Bin; Tang, Chengyuan; Chen, Guochun; Liu, Yu; Zhang, Lei; Liu, Hong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 887-900. DOI: 10.2147/DDDT.S402503
7、Shensong Yangxin Capsule Reduces the Susceptibility of Arrhythmia in db/db Mice via Inhibiting the Inflammatory Response Induced by Endothelium Dysfunction
Author: Zhang, Jiehan; Li, Hongrong; Wang, Dandong; Gu, Jiaojiao; Hou, Yunlong; Wu, Yiling

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 313-330. DOI: 10.2147/DDDT.S392328
8、Review on the Diverse Biological Effects of Glabridin
Author: Zhang, Jianhong; Wu, Xinhui; Zhong, Baiyin; Liao, Qicheng; Wang, Xin; Xie, Yuankang; He, Xiao

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 15-37. DOI: 10.2147/DDDT.S385981